These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28956123)

  • 1. The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study.
    Martens RM; Bechten A; Ingala S; van Schijndel RA; Machado VB; de Jong MC; Sanchez E; Purcell D; Arrighi MH; Brashear RH; Wattjes MP; Barkhof F
    Eur Radiol; 2018 Mar; 28(3):1215-1226. PubMed ID: 28956123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities.
    Bechten A; Wattjes MP; Purcell DD; Aliaga ES; Daams M; Brashear HR; Arrighi HM; Barkhof F
    J Neuroimaging; 2017 May; 27(3):318-325. PubMed ID: 28102639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion.
    Barkhof F; Daams M; Scheltens P; Brashear HR; Arrighi HM; Bechten A; Morris K; McGovern M; Wattjes MP
    AJNR Am J Neuroradiol; 2013 Aug; 34(8):1550-5. PubMed ID: 23436056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.
    Ketter N; Brashear HR; Bogert J; Di J; Miaux Y; Gass A; Purcell DD; Barkhof F; Arrighi HM
    J Alzheimers Dis; 2017; 57(2):557-573. PubMed ID: 28269765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies.
    Brashear HR; Ketter N; Bogert J; Di J; Salloway SP; Sperling R
    J Alzheimers Dis; 2018; 66(4):1409-1424. PubMed ID: 30412493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.
    Sperling R; Salloway S; Brooks DJ; Tampieri D; Barakos J; Fox NC; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Lieberburg I; Arrighi HM; Morris KA; Lu Y; Liu E; Gregg KM; Brashear HR; Kinney GG; Black R; Grundman M
    Lancet Neurol; 2012 Mar; 11(3):241-9. PubMed ID: 22305802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MR imaging features of amyloid-related imaging abnormalities.
    Barakos J; Sperling R; Salloway S; Jack C; Gass A; Fiebach JB; Tampieri D; Melançon D; Miaux Y; Rippon G; Black R; Lu Y; Brashear HR; Arrighi HM; Morris KA; Grundman M
    AJNR Am J Neuroradiol; 2013 Oct; 34(10):1958-65. PubMed ID: 23578674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
    Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
    Delnomdedieu M; Duvvuri S; Li DJ; Atassi N; Lu M; Brashear HR; Liu E; Ness S; Kupiec JW
    Alzheimers Res Ther; 2016 Mar; 8(1):12. PubMed ID: 26925577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.
    Liu E; Wang D; Sperling R; Salloway S; Fox NC; Blennow K; Scheltens P; Schmidt ME; Streffer J; Novak G; Einstein S; Booth K; Ketter N; Brashear HR;
    Neurology; 2018 Mar; 90(10):e877-e886. PubMed ID: 29429971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial Intelligence Assistive Software Tool for Automated Detection and Quantification of Amyloid-Related Imaging Abnormalities.
    Sima DM; Phan TV; Van Eyndhoven S; Vercruyssen S; Magalhães R; Liseune A; Brys A; Frenyo P; Terzopoulos V; Maes C; Guo J; Hughes R; Gabr RE; Huijbers W; Saha-Chaudhuri P; Curiale GG; Becker A; Belachew S; Van Hecke W; Ribbens A; Smeets D
    JAMA Netw Open; 2024 Feb; 7(2):e2355800. PubMed ID: 38345816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.
    Brody M; Liu E; Di J; Lu M; Margolin RA; Werth JL; Booth K; Shadman A; Brashear HR; Novak G
    J Alzheimers Dis; 2016 Oct; 54(4):1509-1519. PubMed ID: 27589523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of 3- and 5-point severity scales to assess ARIA-E.
    Bracoud L; Klein G; Lyons M; Scelsi MA; Wojtowicz J; Bullain S; Purcell D; Fiebach JB; Barakos J; Suhy J
    Alzheimers Dement (Amst); 2023; 15(4):e12503. PubMed ID: 38026755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.
    Hampel H; Elhage A; Cho M; Apostolova LG; Nicoll JAR; Atri A
    Brain; 2023 Nov; 146(11):4414-4424. PubMed ID: 37280110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study.
    Salloway S; Marshall GA; Lu M; Brashear HR
    Curr Alzheimer Res; 2018; 15(13):1231-1243. PubMed ID: 30129411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-Related Imaging Abnormalities in the Era of Anti-Amyloid Beta Monoclonal Antibodies for Alzheimer's Disease: Recent Updates on Clinical and Imaging Features and MRI Monitoring.
    Jeong SY; Suh CH; Kim SJ; Lemere CA; Lim JS; Lee JH
    Korean J Radiol; 2024 Aug; 25(8):726-741. PubMed ID: 39109501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
    Piazza F; Winblad B
    J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.
    Barakos J; Purcell D; Suhy J; Chalkias S; Burkett P; Marsica Grassi C; Castrillo-Viguera C; Rubino I; Vijverberg E
    J Prev Alzheimers Dis; 2022; 9(2):211-220. PubMed ID: 35542992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging of Amyloid-Related Imaging Abnormalities (ARIA).
    Urbach H; Linn J; Hattingen E; Fiebach J
    Rofo; 2024 Apr; 196(4):363-369. PubMed ID: 37995736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.